Key result
A quantitative real-time PCR method successfully determined DMD/BMD carrier status in all subjects, yielding a gene dosage ratio of 0.56±0.11 for carriers and 1.07±0.20 for non-carriers.
Why the study?
Does quantitative real-time PCR accurately determine carrier status in female relatives of DMD/BMD patients?
Cross-Sectional (n=20)
Does quantitative real-time PCR accurately determine carrier status in female relatives of DMD/BMD patients?
Answers are grounded in this paper and cite their sources.
Quantitative real-time PCR using SYBR Green I chemistry is a simple, rapid, reliable, and cost-effective method for routine diagnostics of DMD/BMD deletion carriers.
Duchenne and Becker muscular dystrophy (DMD/BMD) are severe X-linked neuromuscular disorders caused by mutations in the dystrophin gene. Our aim was to optimize a quantitative real-time PCR method based on SYBR? Green I chemistry for routine diagnostics of DMD/BMD deletion carriers. Twenty female relatives of DMD/BMD patients with previously detected partial gene deletions were studied. The relative quantity of the target exons was calculated by a comparative threshold cycle method (??Ct). The carrier status of all subjects was successfully determined. The gene dosage ratio for non-carriers was 1.07?0.20, and for carriers 0.56?0.11. This assay proved to be simple, rapid, reliable and cost-effective.
No takes yet. Share an insight, caveat, or question.
Maksimović et al. (2012) conducted a cross-sectional in Duchenne and Becker muscular dystrophy (DMD/BMD) deletion carriers (n=20). Quantitative real-time PCR method based on SYBR Green I chemistry was evaluated on Carrier status determination via gene dosage ratio. A quantitative real-time PCR method successfully determined DMD/BMD carrier status in all subjects, yielding a gene dosage ratio of 0.56±0.11 for carriers and 1.07±0.20 for non-carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: